
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Vasaka (Adhatoda vasica) contains vasicine alkaloids that act as bronchodilators and expectorants, helping clear respiratory mucus. The herb's quinazoline alkaloids inhibit inflammatory pathways while stimulating mucociliary clearance in the respiratory tract.

Reported Benefits (Provisional)
Origin & History

Vasaka is a shrub native to the Indian subcontinent, known for its medicinal leaves. It has been used traditionally to support respiratory health.
Research Narrative (Provisional)
Studies on Vasaka suggest it may have bronchodilatory and anti-inflammatory effects, with some clinical trials supporting its use for respiratory conditions.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Vasaka (Adhatoda vasica) is not consumed as a food source, so a traditional macronutrient profile (carbohydrates, fats, protein) is not typically characterized. Its significance lies in its bioactive phytochemical composition. Key compounds include: Quinazoline alkaloids — vasicine (peganine, approximately 0.5–1.5% dry weight of leaves) and vasicinone (an oxidation product of vasicine, approximately 0.2–0.5%), which are the primary bronchodilatory and expectorant agents; Essential oils — including small amounts of monoterpenes and sesquiterpenes contributing to antimicrobial activity; Flavonoids — including apigenin, kaempferol, and quercetin glycosides (collectively estimated at 0.3–0.8% dry weight), contributing antioxidant and anti-inflammatory effects; Tannins — approximately 2–5% dry weight, providing astringent and antimicrobial properties; Saponins — present in moderate amounts, contributing to expectorant action by reducing surface tension of mucus; Vitamin C (ascorbic acid) — detected in leaves at approximately 50–130 mg per 100 g fresh weight, contributing to antioxidant defense; Minerals — leaves contain potassium (~1.2–1.8% dry weight), calcium (~0.8–1.4% dry weight), magnesium (~0.3–0.6% dry weight), iron (~15–25 mg per 100 g dry weight), and zinc (~3–5 mg per 100 g dry weight); Crude fiber — approximately 12–18% of dry leaf weight; Beta-sitosterol and other phytosterols — present in minor quantities (~0.05–0.1%), with potential anti-inflammatory roles; Gallic acid and other phenolic acids — contributing to total phenolic content estimated at 3–6 mg GAE/g dry weight. Bioavailability notes: Vasicine is well-absorbed orally and has demonstrated good bioavailability in pharmacokinetic studies, with peak plasma levels reached within 1–2 hours. Vasicinone, formed both in vivo by oxidation and present natively, also shows reasonable oral bioavailability. Flavonoid glycosides have moderate bioavailability, enhanced when consumed with lipids or in decoction form. Tannins may reduce the bioavailability of co-consumed minerals (iron, zinc) through chelation. Traditional preparations as aqueous decoctions (kashaya) or expressed leaf juice (svarasa) optimize extraction of water-soluble alkaloids and phenolics.
Reported Mechanism (Provisional)
Vasaka's primary alkaloids vasicine and vasicinone act as selective phosphodiesterase inhibitors, causing bronchodilation and enhanced mucociliary clearance. These quinazoline compounds also inhibit cyclooxygenase and lipoxygenase pathways, reducing inflammatory mediators like leukotrienes and prostaglandins in respiratory tissues. Additionally, vasicine stimulates beta-2 adrenergic receptors, further promoting bronchial smooth muscle relaxation.
Clinical Narrative (Provisional)
Small clinical trials with 30-60 participants have shown vasaka extracts (standardized to 0.5-1% vasicine) improved cough symptoms and sputum clearance within 7-14 days. A randomized controlled trial of 45 asthmatic patients found 500mg twice daily reduced wheeze frequency by 40% compared to placebo. However, most studies are short-term and limited in size, requiring larger trials to confirm long-term efficacy. Evidence is strongest for acute respiratory symptoms rather than chronic conditions.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







